CRVO logo

CRVO
CervoMed Inc

22,407
Mkt Cap
$65.42M
Volume
43,902.00
52W High
$16.94
52W Low
$1.80
PE Ratio
-2.71
CRVO Fundamentals
Price
$7.07
Prev Close
$7.08
Open
$7.10
50D MA
$8.66
Beta
0.99
Avg. Volume
104,874.86
EPS (Annual)
-$2.02
P/B
1.96
Rev/Employee
$649,198.27
Loading...
Loading...
News
all
press releases
Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last?
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·11d ago
News Placeholder
More News
News Placeholder
Futures Rise As Global Debasement Trade Sends Gold Over $4000
Futures Rise As Global Debasement Trade Sends Gold Over $4000 Futures are higher again, reversing Tuesday's modest Oracle-led decline, and are led by small caps despite additional multi billion tech...
Zero Hedge·19d ago
News Placeholder
CervoMed Gets $11 Price Target From HC Wainwright, Analyst Says Regulatory Outlook For Experimental Dementia Drug Should Be Clear Soon
H.C. Wainwright’s price target implies a premium of nearly 5% from the stock’s closing price on Friday.
Stocktwits·2mo ago
News Placeholder
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +100.00% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of +1,166.67% and +14.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock
The company is now poised to initiate late-stage trials for Neflamapimod.
Stocktwits·3mo ago
News Placeholder
CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains?
CERVOMED INC (CRVO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·3mo ago
News Placeholder
CervoMed Stock Surges On FDA Orphan Drug Nod For FTD Treatment: Retail Optimism Rekindled
The Orphan Drug status provides CervoMed with several key benefits, including tax credits for clinical trial costs, regulatory assistance, and seven years of post-approval market exclusivity.
Stocktwits·11mo ago
News Placeholder
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The...
Globe Newswire·2y ago

Latest CRVO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.